Fresenius SE & Co. KGaA: directors' dealings · Germany · BaFin

About Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA is an international healthcare group listed on Xetra/Frankfurt (DAX/MDAX/SDAX), in Germany, and is widely regarded as one of Europe’s leading providers of essential healthcare products and services. The company was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, near Frankfurt. Fresenius today operates as a therapy-focused healthcare group serving critically and chronically ill patients, combining industrial healthcare products with hospital operations. The group’s business model is built primarily around two operating pillars: Fresenius Kabi and Fresenius Helios. Fresenius Kabi develops and markets injectable generics, biosimilars, clinical nutrition products, and technologies and services related to infusion therapy, anesthesia, and medical devices. Fresenius Helios operates hospitals and clinics, mainly in Germany and Spain, under the Helios and Quirónsalud brands. This structure gives Fresenius a balanced exposure to both healthcare manufacturing and hospital care, with a relatively defensive end-market profile. From a competitive standpoint, Fresenius is positioned as an integrated healthcare solutions provider, with reach across pharmaceutical supply, clinical nutrition, and hospital treatment pathways. That integration is strategically valuable in segments such as sterile injectables, biosimilars, and clinical nutrition, where manufacturing scale, reliability of supply, and regulatory execution matter materially. The group also emphasizes a “local for local” production approach, supported by a manufacturing network spanning Europe, the United States, and Asia. Recent developments show Fresenius continuing to execute its #FutureFresenius transformation agenda. In 2025, management highlighted sustained organic growth, raised full-year guidance, and ongoing progress across key growth areas. The latest company updates also point to continued momentum in biosimilars and pharmaceuticals, improved operating performance, and a stronger balance-sheet profile. For investors, Fresenius remains a notable healthcare name with defensive characteristics, improving margin potential, and a visible medium-term value-creation story anchored in operational discipline and portfolio focus.